Warby Parker (Warby Parker) Debt-to-Equity

: 0.58 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

Warby Parker's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $24.3 Mil. Warby Parker's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $150.2 Mil. Warby Parker's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $301.8 Mil. Warby Parker's debt to equity for the quarter that ended in Dec. 2023 was 0.58.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Warby Parker's Debt-to-Equity or its related term are showing as below:

WRBY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.58 Med: 0.59 Max: 0.61
Current: 0.58

During the past 5 years, the highest Debt-to-Equity Ratio of Warby Parker was 0.61. The lowest was 0.58. And the median was 0.59.

WRBY's Debt-to-Equity is ranked worse than
76.58% of 713 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs WRBY: 0.58

Warby Parker Debt-to-Equity Historical Data

The historical data trend for Warby Parker's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Warby Parker Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.61

0.58

Warby Parker Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial											0.61	0.58	0.56	0.56	0.58

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Warby Parker's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Warby Parker Debt-to-Equity Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Warby Parker's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Warby Parker's Debt-to-Equity falls into.

Warby Parker Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Warby Parker's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(24.286	+	150.171)	/	301.787
	=	0.58

Warby Parker's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(24.286	+	150.171)	/	301.787
	=	0.58

Warby Parker (NYSE:WRBY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Warby Parker Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Warby Parker's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Warby Parker (Warby Parker) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Warby Parker Inc (NYSE:WRBY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

233 Spring Street, 6th Floor East, New York, NY, USA, 10013

Website

https://www.warbyparker.com

Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts to eye exams and vision tests. Brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company primarily derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.

Executives

Steven Clive Miller	officer: Chief Financial Officer	C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
David Abraham Gilboa	director, officer: Co-Chief Executive Officer	C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
Neil Harris Blumenthal	director, officer: Co-Chief Executive Officer	C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
Durable Capital Partners Lp	10 percent owner	4747 BETHESDA AVENUE, SUITE #1002, BETHESDA MD 20814
Teresa Briggs	director	2225 LAWSON LANE, SANTA CLARA CA 95054
Ronald A Williams	director
Jeffrey Jacob Raider	director	C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
Andrew Hunt	director	C/O ELEPHANT PARTNERS, 11 NEWBURY STREET, 5TH FLOOR, BOSTON MA 02116
D1 Capital Partners L.p.	10 percent owner	9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Joel E Cutler	director, 10 percent owner	C/O GENERAL CATALYST PARTNERS, 20 UNIVERSITY ROAD, SUITE 450, CAMBRIDGE MA 02138
Youngme E Moon	director	75 NETWORK DRIVE, BURLINGTON MA 01803
Daniel S. Sundheim	10 percent owner	C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
General Catalyst Group V Lp	10 percent owner	c/o General Catalyst Group Management LL, 20 University Road Ste 450, Cambridge MA 02138
Gabrielle Sulzberger	director	450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017
General Catalyst Group Management Holdings, L.p.	10 percent owner	20 UNIVERSITY ROAD, 4TH FLOOR, CAMBRIDGE MA 02138